RCT Long COVID-19 Rehabilitation

Last updated: June 10, 2024
Sponsor: University Hospital of North Norway
Overall Status: Active - Recruiting

Phase

N/A

Condition

Covid-19

Treatment

Individual follow-ups

One day course

Clinical Study ID

NCT06085911
587293
  • Ages 18-65
  • All Genders

Study Summary

The Coronavirus 2019 (COVID-19) pandemic has resulted in at least four million infections in Norway. The vast majority of cases are diagnosed and followed up in the community, but some with extensive symptoms and large degree of reduced function are referred to regional Covid-clinics. In total this patient group is placing an enormous burden on the already over stretched health care services. As the pandemic subsides the emerging threat of long-term disability from COVID remains to be quantified. Brain fog and cognitive symptoms are common in long COVID in 30% of mild infections resulting in sick leave and loss of daily function, with women overrepresented among long COVID sufferers. The true prevalence and underlying mechanisms of long COVID remains to be quantified. Although vaccination prevents severe infection and death, we have little knowledge on how best to rehabilitate those who suffers from long COVID.

Here we propose to develop knowledge on treatment interventions to counteract disability from long COVID and lessening the burden on health care services. We will conduct a study of where we compare a short group intervention with systematic personalised neurocognitive rehabilitation to document symptom alleviation. Our overarching goal is to develop effective programmes for this evolving disease to reduce the suffering for the patients, and thereby reducing costs for health services and society at large.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Symptoms attributable to long COVID according to WHO definition [14] that affecttheir daily activities

  • Positive Covid test; a home-test, PCR test or serology.

  • Neurocognitive symptoms

  • Age between 18 and 65 years

  • Participant is able and willing to provide informed consent

Exclusion

Exclusion Criteria:

  • Patients that do not want to comply to planned physical study visits

  • Patients who are unable to complete surveys in Norwegian

  • Patients with known chronic neurocognitive disease before Covid-19 or other diseasesthat can explain current symptoms

Study Design

Total Participants: 60
Treatment Group(s): 2
Primary Treatment: Individual follow-ups
Phase:
Study Start date:
November 03, 2023
Estimated Completion Date:
November 30, 2025

Connect with a study center

  • University hospital of North Norway

    Tromsø, Troms 9038
    Norway

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.